Novavax Inc. (NVAX)
Novavax awaits FDA decision on whether its next COVID shot can be offered in US
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said.
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.
Better Buy: Inovio Pharmaceuticals vs. Novavax
Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.
3 Things You Need to Know If You Buy Novavax Today
Novavax stock surged after the company announced a partnership with pharma giant Sanofi. The biotech stock has spent the past few years in the doldrums after sales of its coronavirus vaccine disappointed investors.
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company?
The $10 Stock Jackpot: 3 Speculative Plays That Could Double Overnight
The price-action in some speculative stocks in the recent past is signaling the possible return of the meme stock euphoria. Stocks like Novavax (NASDAQ: NVAX ) doubled overnight, and the rally has even increased.
Shah Capital ends campaign against Novavax board after Sanofi deal
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanofi.
Shah Capital withdraws campaign against three Novavax directors
May 20 (Reuters) - Hedge fund Shah Capital said on Monday that it was withdrawing its preliminary proxy statement and its campaign against the re-election of three directors on Novavax's board. Shah Capital owns an about 7.8% stake in the COVID-19 vaccine maker, according to a regulatory filing on Monday. (Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Novavax recently entered into a lucrative, multitiered deal with Sanofi. The agreement helps improve Novavax's prospects.
Is Novavax Stock a Buy?
Novavax reached a deal with Sanofi recently which sent the stock soaring. The company now expects to generate up to $1.2 billion in revenue this year.
Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?
The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in early June 2022, just before the Fed started increasing rates, and is now 75% below that level, compared to a substantial 40% gain for the S&P 500 during this period.
3 Must-Buy Meme Stocks When Prices Plunge
The meme stock season seems to be back. Novavax (NASDAQ: NVAX ) has surged over 200% in the last month, with big gains coming in a few trading days.
